Company: HURA
Filing Date: 2025-02-07
Form Type: S-4
Source: 0001193125-25-022803
Chunk: 791

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-02-07
Form: S-4
Chunk 791
---
. F-71

TUHURA BIOSCIENSES, INC AND SUBSIDIARY Notes to the condensed consolidated financial statements For the nine months ended September 30, 2024, and 2023 (Unaudited) For the nine months ended September 30, 2024, the Company incurred $ 12.1million of negative cash flows from operations. The Company has approximately $ 19.6million of cash and cash equivalents on hand at September 30, 2024. The Company expects that this will be able to fund future operations, including the expanded clinical trials into the second half of 2025. The Company expects to raise cash through the sale of common shares, issuance of convertible notes, obtaining grants, or commercial partnerships. However, there can be no assurance that any fundraising will be achieved or on commercially reasonable terms, if at all. As such, there is substantial doubt about the Company’s ability to continue as a going concern for the next 12 months from date that the financial statements were available to be issued.

Note 4—Other current assets

Other current assets consist of the following as of September 30, 2024, and December 31, 2023:

|                               |     |   |     Unaudited 
 September 30, 
          2024 |     |   | December 31, 
         2023 |
|:------------------------------|:----|:--|--------------:|:----|:--|-------------:|
| Employee Retention Tax Credit |     | $ |       214,699 |     | $ |      334,443 |
| Clinical trial refund         |     |   |       144,634 |     |   |            — |
| Other current assets          |     |   |       188,117 |     |   |      159,326 |
|                               |     | $ |       547,450 |     | $ |      493,769 |

Note 5—Property and equipment, net

Property and equipment, net consists of the following as of September 30, 2024, and December 31, 2023:

|                                                |     |   |     Unaudited 
 September 30, 
          2024 |   |     |   | December 31, 
         2023 |   |
|:-----------------------------------------------|:----|:--|--------------:|:--|:----|:--|-------------:|:--|